mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance

Abstract

Our findings reveal SOX2-SOX9 as an oncogenic axis that regulates stem cell properties and chemoresistance. We identify that rapamycin abrogate SOX protein expression and provide evidence that a combination of rapamycin and temozolomide inhibits tumor growth in cells with high SOX2/SOX9.